Multiparametric magnetic resonance imaging in prostate cancer: Present and future

Current Opinion in Urology

Volumn 18, Issue 1, 2008, Pages 71-77

  Kurhanewicz, John ^a,b   Vigneron, Daniel ^a   Carroll, Peter ^a   Coakley, Fergus ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Byers Hall ^*  (United States)

Author keywords

Diffusion tensor imaging; Dynamic contrast imaging; Magnetic resonance imaging; Magnetic resonance spectroscopic imaging; Prostate cancer

Indexed keywords

CHOLINE; CITRIC ACID; CONTRAST MEDIUM; GADOLINIUM; POLYAMINE;

CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIFFUSION TENSOR IMAGING; HISTOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROSTATE; PROSTATIC NEOPLASMS;

EID: 37349094329     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3282f19d01     Document Type: Review

References (89)

1. Phillips ME, Kressel HY, Spritzer CE, et al. Prostatic disorders: MR imaging at 1.5 T. Radiology 1987; 164:386-392.
2. Hricak H, White S, Vigneron D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. Radiology 1994; 193:703-709.
3. Hricak H, Dooms GC, Jeffrey RB, et al. Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 1987; 162:331-336.
4. Carrol CL, Sommer FG, McNeal JE, Stamey TA. The abnormal prostate: MR imaging at 1.5 T with histopathologic correlation. Radiology 1987; 163:521-525.
5. Bezzi M, Kressel HY, Allen KS, et al. Prostatic carcinoma: staging with MR imaging at 1.5 T. Radiology 1988; 169:339-346.
6. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002; 16:451-463.
7. Sinha S, Sinha U. In vivo diffusion tensor imaging of the human prostate. Magn Reson Med 2004; 52:530-537.
8. Neeman M, Dafni H. Structural, functional, and molecular MR imaging of the microvasculature. Annu Rev Biomed Eng 2003; 5:29-56.
9. Liney GP, Turnbull LW, Knowles AJ. In vivo magnetic resonance spectroscopy and dynamic contrast enhanced imaging of the prostate gland. NMR Biomed 1999; 12:39-44.
10. Jager GJ, Ruijter ET, van de Kaa CA, et al. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. Radiology 1997; 203:645-652.
11. Jager GJ, Ruijter ET, van de Kaa CA, et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR Am J Roentgenol 1996; 166:845-852.
12. Barentsz JO, Engelbrecht M, Jager GJ, et al. Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging 1999; 10:295-304.
13. Namimoto T, Morishita S, Saitoh R, et al. The value of dynamic MR imaging for hypointensity lesions of the peripheral zone of the prostate. Comput Med Imaging Graph 1998; 22:239-245.
14. Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000; 55:99-109.
15. Padhani AR, Hayes C, Landau S, Leach MO. Reproducibility of quantitative dynamic MRI of normal human tissues. NMR Biomed 2002; 15:143-153.
16. Carroll PR, Coakley FV, Kurhanewicz J. Magnetic resonance imaging and spectroscopy of prostate cancer. Rev Urol 2006; 8 (Suppl 1):S4-S10.
17. Casciani E, Gualdi GF. Prostate cancer: value of magnetic resonance spectroscopy 3D chemical shift imaging. Abdom Imaging 2006; 12 Sep [Epub ahead of print].
18. Coakley FV, Chen I, Qayyum A, et al. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging. BJU Int 2007; 99:41-45. This paper demonstrates how PSA could be used to identify men with progressive disease on active surveillance that would benefit from a MRI/MRSI exam.
19. Costouros NG, Coakley FV, Westphalen AC, et al. Diagnosis of prostate cancer in patients with an elevated prostate-specific antigen level: role of endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 2007; 188:812-816.
20. Futterer JJ, Engelbrecht MR, Jager GJ, et al. Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils. Local staging accuracy of prostate cancer using endorectal coil MR imaging. Eur Radiol 2007; 17:1055-1065. This paper demonstrates that an endorectal coil is important for the most accurate staging of prostate cancer by MRI even at 3T.
21. Girouin N, Mege-Lechevallier F, Tonina Senes A, et al. Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 2007; 17:1498-1509.
22. Hom JJ, Coakley FV, Simko JP, et al. High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features: initial experience. Radiology 2007; 242:483-489. This paper indicates that the metabolic signature for HGPIN is between that of cancer and healthy and is not a confounding factor for the metabolic identification of cancer.
23. Kwock L, Smith JK, Castillo M, et al. Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer. Lancet Oncol 2006; 7:859-868.
24. Manenti G, Squillaci E, Carlani M, et al. Magnetic resonance imaging of the prostate with spectroscopic imaging using a surface coil. Initial clinical experience. Radiol Med (Torino) 2006; 111:22-32.
25. Mueller-Lisse UG, Swanson MG, Vigneron DB, Kurhanewicz J. Magnetic resonance spectroscopy in patients with locally confined prostate cancer: association of prostatic citrate and metabolic atrophy with time on hormone deprivation therapy, PSA level, and biopsy Gleason score. Eur Radiol 2007; 17:371-378.
26. Pels P, Ozturk-Isik E, Swanson MG, et al. Quantification of prostate MRSI data by model-based time domain fitting and frequency domain analysis. NMR Biomed 2006; 19:188-197.
27. Shukla-Dave A, Hricak H, Kattan MW, et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int 2007; 99:786-793. This is a large presurgical patient cohort study that demonstrated the utility of adding MRI/MRSI findings to a biopsy-based nomogram for improved prediction of insignificant disease. This is a very important paper from the standpoint of selecting active surveillance patients. Similar studies need to be performed to determine the incremental value of performing the MR I/MRSI exam at 3T and adding DTI and DCE data to the exam.
28. Taouli B. MR spectroscopic imaging for evaluation of prostate cancer. J Radiol 2006; 87 (2 Pt 2):222-227.
29. Testa C, Schiavina R, Lodi R, et al. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 2007; 244:797-806.
30. van Lin EN, Futterer JJ, Heijmink SW, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006; 65:291-303.
31. Wang L, Hricak H, Kattan MW, et al. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. Radiology 2007; 242:182-188. This presurgical patient cohort study demonstrated the utility of adding MRI/MRSI findings to a biopsy-based nomogram for improved prediction of SVI.
32. Wang L, Zhang J, Schwartz LH, et al. Incremental value of multiplanar cross-referencing for prostate cancer staging with endorectal MRI. AJR Am J Roentgenol 2007; 188:99-104.
33. Miao H, Fukatsu H, Ishigaki T. Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. Eur J Radiol 2007; 61:297-302.
34. Pickles MD, Gibbs P, Sreenivas M, Turnbull LW. Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T. J Magn Reson Imaging 2006; 23:130-134.
35. Mulkern RV, Barnes AS, Haker SJ, et al. Biexponential characterization of prostate tissue water diffusion decay curves over an extended b-factor range. Magn Reson Imaging 2006; 24:563-568.
36. Manenti G, Squillaci E, Di Roma M, et al. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissue using thin-slice echo-planar imaging. Radiol Med (Torino) 2006; 111:1124-1133.
37. Hacklander T, Scharwachter C, Golz R, Mertens H. Value of diffusionweighted imaging for diagnosing vertebral metastases due to prostate cancer in comparison to other primary tumors. Rofo 2006; 178:416-424.
38. Gibbs P, Pickles MD, Turnbull LW. Diffusion imaging of the prostate at 3.0 tesla. Invest Radiol 2006; 41:185-188.
39. Villers A, Puech P, Mouton D, et al. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006; 176 (6 Pt 1):2432-2437. This study demonstrated the ability of DCE MRI at 3T to estimate intraglandular tumor volume with pathologic correlation.
40. Dafni H, Kim S, Panda K, et al. Signal loss in DCE-MRI associated with tumor progression in prostate cancer bone metastasis model [abstract]. In: Proceedings of the 14th Scientific Meeting of the Society of Magnetic Resonance in Medicine; 6-12 May 2006; Seattle. Berkeley: ISMRM; 2006. Abstract 118.
41. Futterer JJ, Heijmink SW, Scheenen TW, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006; 241:449-458. This determines the accuracies of T2-weighted MR imaging, dynamic contrast material-enhanced MR imaging, and quantitative three-dimensional (3D) proton MR spectroscopic imaging using whole-mount histopathologic section findings as the reference standard.
42. Kirkham AP, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006; 50:1163-1174.
43. Prando A. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. Int Braz J Urol 2006; 32:727-728.
44. Kim CK, Park BK, Kim B. Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging. Journal of Computer Assisted Tomography 2006; 30:7-11.
45. Cunningham CH, Vigneron DB, Chen AP, et al. Design of flyback echo-planar readout gradients for MR spectroscopic imaging. Magn Reson Med 2005; 54:1286-1289.
46. Scheenen TW, Gambarota G, Weiland E, et al. Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T. Magn Reson Med 2005; 53:1268-1274.
47. Chen AP, Cunningham CH, Ozturk-Isik E, et al. High-speed 3T MR spectroscopic imaging of prostate with flyback echo-planar encoding. J Magn Reson Imaging 2007; 25:1288-1292.
48. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology [see comments]. J Urol 2000; 164:400-404.
49. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer. Localization with three-dimensional proton MR spectroscopic imaging: clinicopathologic study. Radiology 1999; 213:473-480.
50. Hasumi M, Suzuki K, Taketomi A, et al. The combination of multivoxel MR spectroscopy with MR imaging improve the diagnostic accuracy for localization of prostate cancer. Anticancer Res 2003; 23 (5b):4223-4227.
51. Portalez D, Malavaud B, Herigault G, et al. Predicting prostate cancer with dynamic endorectal coil MR and proton spectroscopic MR imaging. J Radiol 2004; 85 (12 Pt 1):1999-2004.
52. Squillaci E, Manenti G, Mancino S, et al. MR spectroscopy of prostate cancer. Initial clinical experience. J Exp Clin Cancer Res 2005; 24:523-530.
53. Vilanova JC, Barcelo J. Prostate cancer detection: MR spectroscopic imaging. Abdom Imaging 2007; 32:253-261.
54. Yu KK, Scheidler J, Hricak H, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999; 213:481-488.
55. Wang L, Hricak H, Kattan MW, et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006; 238:597-603. This large presurgical patient cohort study demonstrated the utility of adding MRI/MRSI findings to a biopsy-based nomogram for improved prediction of organ confined prostate cancer. This is a very important paper from the standpoint of selecting patients that are appropriate candidates for focal therapy. Similar studies need to be performed to determine the incremental value of performing the MR I/MRSI exam at 3T and adding DTI and DCE data to the exam.
56. Kurhanewicz J, Vigneron DB, Males RG, et al. The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am 2000; 38:115-138; viii-ix.
57. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005; 234:804-814.
58. Chen AP, Cunningham CH, Kurhanewicz J, et al. High-resolution 3D MR spectroscopic imaging of the prostate at 3 T with the MLEV-PRESS sequence. Magn Reson Imaging 2006; 24:825-832.
59. Cunningham CH, Vigneron DB, Marjanska M, et al. Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T. Magn Reson Med 2005; 53:1033-1039.
60. Chen AP, Albers M, Kohler SJ, et al. High-resolution hyperpolarized C-13 spectroscopic imaging of the TRAMP mouse at 3T [abstract]. In: Proceedings of the 14th Scientific Meeting of the Society of Magnetic Resonance in Medicine; 6-12 May 2006; Seattle. Berkeley: ISMRM; 2006. p. 587.
61. Noworolski SM, Henry RG, Vigneron DB, Kurhanewicz J. Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI. Magn Reson Med 2005; 53:249-255.
62. Jeukens CR, van den Berg CA, Donker R, et al. Feasibility and measurement precision of 3D quantitative blood flow mapping of the prostate using dynamic contrast-enhanced multislice CT. Phys Med Biol 2006; 51:4329-4343.
63. Hara N, Okuizumi M, Koike H, et al. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005; 62:140-147.
64. Schlemmer HP, Merkle J, Grobholz R, et al. Can preoperative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 2004; 14:309-317.
65. Choi YJ, Kim JK, Kim N, et al. Functional MR imaging of prostate cancer. Radiographics 2007; 27:63-75.
66. Katz S, Rosen M. MR imaging and MR spectroscopy in prostate cancer management. Radiol Clin North Am 2006; 44:723-734; viii.
67. Kozlowski P, Chang SD, Jones EC, et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis: correlation with biopsy and histopathology. J Magn Reson Imaging 2006; 24:108-113.
68. Kumar V, Jagannathan NR, Kumar R, et al. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Magn Reson Imaging 2006; 24:541-548.
69. Sato C, Naganawa S, Nakamura T, et al. Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005; 21:258-262.
70. Carroll PR, Presti JJ, Small E, Roach MR. Focal therapy for prostate cancer 1996: maximizing outcome. Urology 1997; 49 (suppl 3A):84-94.
71. Hricak H, White S, Vigneron D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal: pelvic phased-array coils. Radiology 1994; 193:703-709.
72. Okamura T, Umemoto Y, Yamashita K, et al. Pitfalls with MRI evaluation of prostate cancer detection: comparison of findings with histopathological assessment of retropubic radical prostatectomy specimens. Urol Int 2006; 77:301-306. This good recent study looked at the accuracy of MRI for prostate cancer detection with pathologic correlation.
73. Hom JJ, Coakley FV, Simko JP, et al. Prostate cancer: endorectal MR imaging and MR spectroscopic imaging-distinction of true-positive results from chance-detected lesions. Radiology 2006; 238:192-199. This is an important paper from the stand-point of ensuring uniformity of scientific studies investigating the accuracy of MRSI for the detection of prostate cancer.
74. Heijmink SW, Futterer JJ, Hambrock T, et al. Prostate cancer: body-array versus endorectal coil MR imaging at 3 T: comparison of image quality, localization, and staging performance. Radiology 2007; 244:184-195. This is an important paper from the stand-point that it demonstrates the clinical benefits of using a endorectal coil at 3T.
75. 2 weighted imaging.
76. Dhingsa R, Qayyum A, Coakley FV, et al. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: effect of clinical data on reader accuracy. Radiology 2004; 230:215-220.
77. Hasumi M, Suzuki K, Oya N, et al. MR spectroscopy as a reliable diagnostic tool for localization of prostate cancer. Anticancer Res 2002; 22 (2B):1205-1208.
78. Coakley FV, Kurhanewicz J, Lu Y, et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002; 223:91-97.
79. D'Amico AV, Chang H, Holupka E, et al. Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. Urology 1997; 49:385-391.
80. Smith JA Jr, Scardino PT, Resnick MI, et al. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multiinstitutional trial. J Urol 1997; 157:902-906.
81. Yu KK, Hricak H, Alagappan R, et al. Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology 1997; 202:697-702.
82. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150:110-114.
83. Steyerberg EW, Roobol MJ, Kattan MW, et al. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007; 177:107-112.
84. Kattan MW, Eastham J. Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer. Clin Prostate Cancer 2003; 1:221-226.
85. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006; 98:715-717.
86. Wang L, Hricak H, Kattan MW, et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006; 238:597-603. This is the first manuscript to demonstrate that the addition of MRI/MRSI data to a clinical nomogram significantly increases the accuracy of predicting indolent disease.
87. Han M, Partin AW, Piantadosi S, et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001; 166:416-419.
88. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95:868-878.
89. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002; 94:981-990.